Dennis Houghton Email & Phone Number

Santa Barbara, California, United States

Xiretsa is a startup company with the goal of commercializing a new class of antibiotics based on anti-infective conjugated electrolytes (ACEs). ACEs comprise a new class of broad-spectrum antibiotics that target G+ and G- bacteria and multi-species biofilms included in the WHO & CDC Priority Pathogens’ List. Differentiating features of ACEs include: (a) a molecular scaffold platform that enables rapid synthesis, product scaleup and the generation of derivatives for specific indications, (b) their properties can be tuned to balance efficacy and safety (our team has generated several hit compounds up to date), (c) membrane targeting activity that offers superiority over classical antimicrobials for treating slow-growing, dormant, and persistent infections, (d) a lower level of resistance relative to conventional antibiotics. Xiretsa’s technology has been developed through funding at the University of California, Santa Barbara (UCSB), the Singapore Center for Environmental Life Sciences Engineering (SCELSE), and the National University of Singapore (NUS). These efforts have led to understanding the molecular features that dominate MIC, cytotoxicity, and in vivo toxicity.

Pasadena, California, United States

GI Logic is a Southern California-based company specializing in the design, manufacture and distribution of biosensors and related medical technologies crafted specifically for the reading and analysis of gastrointestinal activity.Our mission is to continually innovate and evolve medical devices that help contribute to human welfare and advance the field of gastroenterology.Gastrointestinal (GI) disorders are highly prevalent in both inpatient and outpatient settings. A recent NIH-commissioned burden of illness study revealed that there are over 70 million ambulatory care visits every year with a GI disorder listed as the first diagnosis. This number swelled to over 100 million visits when including GI disorders anywhere on the diagnosis list – the equivalent of nearly 36,000 outpatient visits per 100,000 residents in the U.S.GI disorders have enormous direct and indirect societal costs. The total direct cost of care for GI disorders is estimated at $100 billion a year. Add the considerable indirect costs and the total exceeds $140 billion. With the aging of the American population and the rising incidence of obesity, it is certain that the economic impact GI disorders will burgeon over the next decade and beyond.GI Logic was created to address an urgent need for convenient, low cost, sensor systems that can be deployed rapidly in the hospital, clinic and home for diagnosis of digestive disorders. These sensor systems must provide network communication capability for both local area mobile computing devices as well as communication to remote assets.Clinicians have traditionally relied on either the basic capabilities of a stethoscope or on invasive, often complex, methods to diagnose and treat increasingly common GI disorders. Through innovation and research, GI Logic aims to develop a range of new tools to help clinicians improve patient care and advance the field of GI medicine.

Santa Barbara, California, United States

Santa Barbara, California, United States

Chicago, Il

Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.

Cubist Pharmaceuticals, Inc. was a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Cubist was acquired by Merck in March 2015.

MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.

Revitas, a leader in Enterprise Revenue Dynamics, delivers integrated solutions for contracts, pricing, and compliance that drive higher profitability and lower risk. Revitas empowers companies to optimize contract performance by defining, managing, and analyzing complex, multi-tier pricing incentives and enables positive proof of compliance with commercial, financial, and industry requirements. Powered by the secure, scalable, and standards-based Flex® platform, Revitas® applications speed time to market and improve visibility across B2B relationships.